Patients:
Patients with high-risk TM receiving F-araA based conditioning regimen
prior to HCT between 2010 and 2019 were recruited after obtaining
written informed assent or consent from the patient/parents
respectively. This study was approved by the Institutional review board.
All patients were risk-stratified based on Vellore risk classification
as published previously 24. All patients received
F-araA at a dose of 40mg/m2/day x 4 days as 1hr
infusion from day -5 to day -2 and Treo as 14g/m2/day
x 3 days at the rate 5g/hr from day -5 to day -3 and a single dose of
Thiotepa on day -6 prior to HCT. Cyclosporine and short course
methotrexate was used as GVHD prophylaxis 1.